Skip to main content
. 2018 Jan 26;9(2):123. doi: 10.1038/s41419-017-0132-2

Fig. 5. BEZ235 had antitumor effects partly through the PI3K/Akt pathway in PTX-resistant GC.

Fig. 5

a BEZ235 (45 mg/kg/day, daily, by gavage) with or without PTX (10 mg/kg/week, weekly, ip) given to mice bearing HGC-27R tumors for 21 days. Tumor volume expressed as mean ± S.D. (n = 5 per group). c FFPE sections stained with Ki-67 for IHC analysis. Original magnification, ×200. b Tumor lysates immunoblotted for corresponding proteins